Post
  • From Twitter

Nice summary of ⁦@michal_stanczak⁩ and ⁦@LImmunotherapy⁩’s recent publication in ⁦@ScienceTM⁩ on Siglec/sialoglycan axis as target for cancer immune therapy, with the ⁦@Palleon_Pharma⁩ team and us as collaborators. #glycotime

Replies
No replies yet